Gabapentin vs Pregabalin for Nerve Pain: Differences and Review Questions
Understand how these medicines are assessed, what a useful treatment trial looks like, and what to check before a change.
Practical comparison
What to compare before choosing or changing treatment
This compares treatment questions for adults. Licensed indications, schedules and formulations vary by country. It is a discussion aid for a medicine review.
What to compare before choosing or changing treatment
| Question | Gabapentin | Pregabalin |
|---|---|---|
| What does the name identify? | A medicine used for selected nerve-pain and seizure indications | A related medicine with its own indications and formulation instructions |
| Can I compare the milligrams directly? | Use the exact formulation and prescribed schedule | A milligram amount cannot establish an equivalent gabapentin dose |
| What affects the plan? | Response, tolerability, kidney function and other medicines | The same factors matter, with a separate product-specific assessment |
| What should a review measure? | Pain, sleep, function and unwanted effects | Pain, sleep, function and unwanted effects |
How do gabapentin and pregabalin compare?
Both medicines alter signalling involved in nerve pain. They are prescribed for specific clinical problems and can help some people whose pain follows nerve damage. An individual may find one more helpful or easier to tolerate. The larger milligram number on a pack does not tell you which treatment will give better relief.
UK NICE guidance includes gabapentin and pregabalin among initial options for neuropathic pain outside trigeminal neuralgia, with sciatica assessed under a separate guideline. The existing gabapentin guide covers product identification and precautions for that medicine in more detail.
Check what is causing the pain first
Nerve pain may feel burning, electric, shooting or unusually painful to light touch. A clinician also looks at the distribution, sensation, strength and medical history. Diabetes, shingles and an injury can lead to different investigations and follow-up even when a similar pain medicine is considered.
Keep the onset and location of pain in your notes. Say whether it follows a rash, whether there is numbness and whether you have weakness. Get emergency assessment for sudden new weakness, new loss of bladder or bowel control, new difficulty starting or passing urine, or numbness around the genitals or bottom. These can signal a serious neurological problem. The evaluation of the cause remains part of care after pain treatment begins.
Sciatica and low back pain need their own treatment pathway. UK NICE NG59 advises against offering gabapentinoids for either condition. If one is already prescribed for that reason, arrange a review of benefit, risks and any withdrawal plan rather than stopping it abruptly.
Give a treatment trial a measurable goal
A useful goal might be sleeping with fewer interruptions, walking to a nearby shop or tolerating clothing over a painful area. Record the activity at the start and repeat the same observation during the trial. Add a pain score if your team asks for one, and keep the timing consistent.
NHS information explains that the full effect can take a few weeks. Increasing a medicine gradually can also mean the first days do not represent the final treatment trial. Ask when the team will review benefit and how they want you to report problems earlier. Feeling sleepy alone does not establish pain improvement.
Why kidney function and the full pack name matter
The body clears these medicines through the kidneys, so impaired kidney function can change the appropriate amount and frequency. Give the prescriber your kidney history and mention recent dehydration or illness. Older results may need review if health has changed. The eGFR and urine ACR guide explains what the common kidney tests describe.
Read every ingredient on a combination pack. A pregabalin product with nortriptyline, methylcobalamin or another medicine has additional ingredients to consider. When comparing a single-ingredient prescription with a catalogue listing, ask the pharmacist to match the full formulation.
Drowsiness, dizziness, swelling and everyday safety
Both medicines can cause dizziness or sleepiness. Before driving, using tools or climbing steps, check how the treatment affects your alertness and balance. Record when the effect occurs in relation to the dose. A medicine review may consider whether the timing, amount or treatment choice needs adjustment.
Tell the team about leg swelling, weight changes or difficulty concentrating. Include whether these changes began after treatment started or increased. Seek urgent help for a severe allergic reaction, a blistering rash or thoughts of harming yourself. A caregiver can also report unusual behaviour or marked changes in alertness.
Why opioids, sleeping tablets and alcohol need special attention
The US FDA warns about serious breathing problems with gabapentin or pregabalin in people with risk factors, including opioid treatment, other sedating medicines and reduced lung function. Take a complete list to the pharmacist, including sleeping tablets and sedating cold or allergy products.
Get emergency help if someone becomes difficult to wake, has slow or shallow breathing, or develops blue or grey lips. Give responders the medicine names and the times last taken. UK MHRA advice also identifies respiratory risk with pregabalin and advises avoiding alcohol during treatment.
Pregnancy plans and contraception need an early review
Tell the prescriber if you are pregnant, planning pregnancy or breastfeeding. UK NHS information says gabapentin is not generally recommended in pregnancy because safety information is limited. Some pregabalin studies suggest a small increase in birth-defect risk, although the findings are not uniform. The decision weighs possible risks against the benefit of treatment, including seizure control when epilepsy is present.
The NHS recommends effective contraception while taking pregabalin and a treatment review before a planned pregnancy. If pregnancy occurs, contact the prescriber promptly and do not stop either medicine abruptly without medical advice. Ask for a pregnancy-specific plan, particularly when the medicine is also treating epilepsy.
Switching between the medicines needs a written plan
A clinician may suggest a change if the diagnosis fits but benefit is insufficient or adverse effects limit treatment. NHS Specialist Pharmacy Service describes different approaches to switching and notes that evidence is limited. The chosen approach depends on the current regimen, health conditions and ability to monitor the change.
Ask which medicine to take on each day, whether there is any overlap and when to call about new symptoms. Keep the written instructions beside the packs. If directions from two services conflict, have the pharmacist reconcile them before the next planned change. An online conversion ratio cannot account for all these factors.
Stopping treatment and interpreting returning symptoms
Abruptly stopping either medicine can produce withdrawal symptoms. NHS information lists problems such as anxiety, sweating, poor sleep, nausea and pain. In January 2026, the MHRA strengthened information on dependence, addiction, withdrawal and tolerance for these medicines. The prescriber can agree a gradual reduction and adapt it if symptoms develop. Epilepsy adds a further reason to coordinate changes with the treating team.
If symptoms return during reduction, record what changed and when. Returning nerve pain, withdrawal and another health problem can need different responses. Contact the team for advice on the next step. Avoid using a leftover higher dose to manage the change yourself.
Details to include in a product enquiry
For an existing prescription, the Gabapentin 300 mg Capsules listing can help identify a specific presentation. Include the exact ingredient, strength, form and prescribed release wording when asking for pack information. A professional enquiry can also state destination and quantity.
Bring the quotation back to the pharmacist if the offered brand, form or ingredients differ from the prescription. Ask the receiving organisation to check its product and documentation requirements. A product match and a clinical decision are separate steps in arranging supply.
Export product support
Need product, pack, and documentation details?
Global Medicines Export can support international B2B enquiries for product availability, strengths, pack information, quotation coordination, and shipment documentation review.
Common questions
Is pregabalin stronger than gabapentin?
The milligram amounts cannot establish that. A useful comparison considers the diagnosis, the prescribed schedule, improvement in daily activities and side effects during a properly reviewed trial.
What if I feel sleepy before the pain improves?
Record when the sleepiness occurs and avoid driving while affected. Tell the prescriber if it interferes with daily life, causes falls or makes it difficult to follow the treatment plan.
Can the two medicines be taken together?
Tell the prescriber about both packs. They have similar actions and overlapping adverse effects. Any overlap during a switch needs explicit instructions and monitoring.
Can I take an occasional sleeping tablet with them?
Have a pharmacist check the exact sleeping medicine and all other sedating products. Combined sedation and breathing risk can be important, especially with opioids or lung disease.
What should I do after missing a dose?
Follow the leaflet for your exact medicine and schedule. Avoid taking extra doses together. A pharmacist can advise if the next dose is close or you have missed several.
Does adding a vitamin make a pregabalin product equivalent?
Read the complete ingredients and release form. A combination product requires its own suitability check even when it contains the same pregabalin strength.
What should I bring to a pain review?
Bring the packs, current schedule, other medicines, recent kidney results, pain timeline and a record of sleep, activity and unwanted effects.
Important medical note
This article is for general educational information only. It is not medical advice, diagnosis, or a treatment plan. Medicines should be used only under the guidance of a qualified healthcare professional. Product availability, export documentation, and quotation support do not imply that a medicine is appropriate for any individual patient.
References
- NICE CG173 recommendations on neuropathic pain
- NHS gabapentin common questions and withdrawal
- NHS pregabalin common questions
- NHS SPS guidance on switching gabapentin and pregabalin
- FDA gabapentinoid breathing safety communication
- MHRA pregabalin and severe respiratory depression
- MHRA January 2026 strengthened gabapentinoid safety information
- NHS sciatica and neurological emergency symptoms
- NHS gabapentin pregnancy, breastfeeding and fertility
- NHS pregabalin pregnancy, contraception and fertility
- NICE NG59 low back pain and sciatica recommendations